The C1 esterase inhibitor function test checks whether C1 inhibitor protein can control the enzyme systems that generate bradykinin. It is the most direct laboratory test for hereditary angioedema caused by C1 inhibitor deficiency or dysfunction. People with this disorder develop recurrent, non-itchy swelling of the skin, digestive tract, or airway, often without hives and without a dependable response to standard allergy medicines.
Functional testing is necessary because protein quantity can be misleading. In type I hereditary angioedema, both the amount and activity of C1 inhibitor are low. In type II disease, the blood may contain a normal or increased amount of protein, but it does not work correctly. A low functional result must still be confirmed and interpreted with C1 inhibitor antigen, C4, symptoms, treatment exposure, and specimen quality. The assay is technically sensitive, so an unexpected low value should not be treated as a final diagnosis until the full pattern has been reviewed.
- C1 inhibitor function measures activity: It shows whether the protein controls target enzymes, not merely whether it is present.
- Low function occurs in both type I and type II hereditary angioedema: Antigen testing separates low-quantity from dysfunctional-protein patterns.
- A result below about 50% of normal is strongly suspicious: Exact cutoffs and equivocal zones depend on the laboratory method.
- Poor sample handling can cause a false low result: Prompt serum separation and freezing may be required.
- Low function with low C1q suggests acquired deficiency: Adult onset and no family history make this pattern more important.
- Normal function redirects the workup: ACE inhibitor angioedema, mast-cell swelling, and hereditary angioedema with normal C1 inhibitor remain possible.
Table of Contents
- Function Is Different From Concentration
- How C1 Inhibitor Prevents Swelling
- When Functional Testing Is Useful
- Assay Methods and Specimen Quality
- Reading the Result
- Patterns That Separate HAE Types
- Discordant and Borderline Results
- Diagnosis, Follow-Up, and Safety
Function Is Different From Concentration
C1 inhibitor is a circulating regulatory protein encoded by the SERPING1 gene. A quantitative antigen test counts the protein, while the functional assay tests its ability to inhibit a target enzyme. That distinction is essential because a protein can be present but defective.
The two established forms of C1-inhibitor-deficient hereditary angioedema have different quantity patterns:
- HAE type I: C1 inhibitor antigen is low and function is low.
- HAE type II: C1 inhibitor antigen is normal or high, but function is low.
Type II disease can be missed when only a concentration test is ordered. The circulating protein may look reassuring on paper even though it cannot regulate the contact system adequately. For this reason, guidelines recommend assessing function as part of the initial biochemical evaluation when recurrent bradykinin-mediated angioedema is suspected.
Functional activity is generally reported as a percentage of normal. Some laboratories classify more than 67% as normal, 41%–67% as equivocal, and less than 41% as abnormal. Other laboratories use a cutoff near 50% or apply method-specific intervals. A report must be interpreted against its own reference range, not a number found online or on an older test.
The result is not equivalent to “percent immune function.” It describes one protein’s performance in a laboratory reaction. It does not measure antibody strength, allergy severity, general resistance to infection, or the chance that an attack will occur on a particular day.
The companion C1 esterase inhibitor antigen test remains necessary because functional loss alone does not classify the disorder. Quantity, activity, and complement consumption together create the useful diagnostic pattern.
How C1 Inhibitor Prevents Swelling
C1 inhibitor restrains several proteases, including activated C1r and C1s in the classical complement pathway, factor XIIa, plasma kallikrein, and plasmin. Its control of factor XII and kallikrein is especially relevant to angioedema.
When contact-system activation is not adequately restrained, kallikrein cleaves high-molecular-weight kininogen and releases bradykinin. Bradykinin binds B2 receptors on blood vessels and increases vascular permeability. Fluid then leaves the circulation and enters deeper tissues.
This mechanism produces a characteristic clinical pattern:
- Swelling tends to be deep, firm, or painful rather than itchy.
- Hives are usually absent.
- An episode often builds over hours and lasts two to five days untreated.
- The bowel can swell, causing severe cramping, vomiting, diarrhea, or temporary abdominal fluid.
- Laryngeal swelling can block the airway and become fatal.
- Antihistamines and corticosteroids usually do not stop a pure bradykinin attack.
Triggers may include dental procedures, surgery, minor trauma, infection, emotional stress, estrogen exposure, or no identifiable event. Attack frequency varies from rare episodes to frequent disability, even among relatives with the same SERPING1 variant.
C4 often falls because uncontrolled activation consumes early classical complement components. A C4 blood test is therefore a useful partner, but it is not a substitute for function. Some affected people have normal C4 between attacks, and low C4 has many other causes.
C1 inhibitor function is also reduced in acquired C1 inhibitor deficiency. In that disorder, the protein may be consumed or neutralized by autoantibodies, often in association with a B-cell or autoimmune condition. The same bradykinin pathway produces swelling, but the patient’s age, family history, C1q level, and associated findings differ.
When Functional Testing Is Useful
The test is most useful for recurrent angioedema without wheals or itching. A clinician may order it after one severe unexplained episode, especially if the airway was involved, or after a pattern of repeated skin or abdominal attacks.
Clinical clues include:
- Recurrent swelling of the face, lips, hands, feet, genitals, tongue, or throat
- Repeated abdominal attacks with normal health between episodes
- Symptoms beginning in childhood or adolescence
- Similar swelling in a parent, sibling, child, or more distant relative
- Poor response to adequate antihistamine treatment
- Swelling after dental work or surgery
- A flat, non-itchy prodromal rash called erythema marginatum
- Unexplained recurrent laryngeal edema
First-degree relatives of a person with confirmed HAE type I or II should be offered testing even if they have never had symptoms. The condition is usually autosomal dominant, so each child of an affected parent has a 50% chance of inheriting the causal variant. A negative family history does not exclude HAE because new variants occur and relatives may be undiagnosed.
Functional testing also helps evaluate suspected acquired angioedema due to C1 inhibitor deficiency. This is more likely when attacks begin in middle or later adulthood, there is no family history, and laboratory studies show low C1q or evidence of monoclonal B-cell disease.
The test is not designed to confirm ordinary food allergy, chronic spontaneous urticaria, or histamine-mediated angioedema. Those conditions often involve hives and itching and may respond to antihistamines. However, a patient can have more than one swelling mechanism, so the clinician should not rely on a single symptom to classify every episode.
A normal functional result can be informative. It makes classic type I and II HAE less likely when repeated under reliable conditions. It does not exclude hereditary angioedema with normal C1 inhibitor, ACE inhibitor-induced angioedema, or other bradykinin disorders.
Assay Methods and Specimen Quality
Functional C1 inhibitor testing is more technically demanding than measuring antigen concentration. Laboratories commonly use chromogenic assays or enzyme immunoassays that measure formation of a C1 inhibitor-enzyme complex. The methods do not always produce identical values, especially near the cutoff.
A chromogenic assay typically evaluates how well the patient’s C1 inhibitor blocks an added protease and then measures residual enzyme activity through a color-producing substrate. Some ELISA-based methods measure complexes formed between C1 inhibitor and C1s or another target. Newer approaches may use plasma kallikrein or dried blood spots, but availability and validation differ.
Specimen handling can alter activity. Depending on the laboratory, instructions may require:
- Collection in a plain red-top tube
- Prompt separation of serum from blood cells
- Freezing within a short interval after collection
- Frozen transport to the reference laboratory
- Avoidance of repeated thawing and refreezing
- Rejection of grossly hemolyzed or lipemic samples
The collection center should follow the performing laboratory’s current instructions rather than a generic protocol. A sample left warm for too long can lose functional activity and create a false abnormal result.
Fasting requirements vary. Many laboratories do not require fasting, while some reference protocols prefer it. Food intake is usually less important than specimen processing. The ordering office should verify the exact test catalog instructions before collection.
Recent treatment can also distort the result. C1 inhibitor concentrate, recombinant C1 inhibitor, or fresh frozen plasma can raise measured function temporarily. Long-term androgen therapy may alter levels. A diagnostic specimen is ideally collected before replacement treatment when safe, but emergency therapy must never be delayed to preserve a laboratory result.
Infants need special consideration. C1 inhibitor values and other complement proteins can be lower in early life. Testing a child from an affected family is still important, but abnormal biochemical results may need confirmation after the first year. Testing for a known familial SERPING1 variant can sometimes clarify status earlier.
Reading the Result
A low result means that C1 inhibitor in the sample did not suppress the assay target as expected. It does not reveal why. The main categories are inherited dysfunction, acquired deficiency, temporary or treatment-related alteration, and technical error.
Clearly low activity
Repeated activity below approximately 50% of normal strongly supports C1-inhibitor-deficient angioedema when the clinical picture and companion tests agree. Many untreated patients with HAE type I or II have substantially reduced function, not merely a value one or two points below range.
Low function becomes more persuasive when C4 is low and attacks occur without hives. Antigen determines whether the pattern is type I or type II. A low C1q in an adult with no family history shifts concern toward acquired deficiency.
Equivocal activity
A borderline zone is not diagnostic. Values can be affected by specimen delay, assay variability, recent replacement therapy, acute illness, and the laboratory method. The next step is usually repeat testing with careful handling and simultaneous antigen and C4 measurements.
Repeated equivocal values in a patient with a highly suggestive history may justify testing at a specialist reference laboratory, review of the raw method, and SERPING1 genetic analysis. A patient with weak clinical evidence and one borderline result should not be labeled with HAE prematurely.
Normal activity
Normal function argues against type I and type II HAE, especially when antigen and C4 are also normal on more than one occasion. It does not exclude every bradykinin disorder. HAE with normal C1 inhibitor is diagnosed through clinical criteria, family history, exclusion of more common causes, and genetic testing when a known variant is present.
A normal result obtained soon after C1 inhibitor concentrate or plasma may not reflect the untreated baseline. The report should always be interpreted with treatment dates.
High activity
Values above the upper reference limit usually have little diagnostic significance. They do not indicate that a person is protected from angioedema, nor do they measure excessive immune strength. Elevated results may reflect method variation, replacement therapy, or increased protein production. The clinical focus remains on whether activity is deficient.
Patterns That Separate HAE Types
Functional activity provides the shared abnormality in HAE type I and type II. Antigen and C1q then help classify the cause.
| Likely category | C1 inhibitor function | C1 inhibitor antigen | C4 | C1q |
|---|---|---|---|---|
| HAE type I | Low | Low | Usually low | Usually normal |
| HAE type II | Low | Normal or high | Usually low | Usually normal |
| Acquired C1 inhibitor deficiency | Low | Often low | Low | Often low |
| HAE with normal C1 inhibitor | Normal | Normal | Usually normal | Normal |
| ACE inhibitor angioedema | Normal | Normal | Usually normal | Normal |
| Mast-cell-mediated swelling | Normal | Normal | Usually normal | Normal |
These are typical patterns, not rigid rules. C4 can occasionally be normal in confirmed HAE, and C1q can be normal in acquired disease. Laboratory methods can disagree. The diagnosis is strongest when repeated biochemical findings, symptoms, age at onset, family history, and genetic evidence align.
Type II disease deserves special attention because antigen may be above normal. A high protein quantity with low activity is not contradictory; the assay is detecting dysfunctional protein. Ordering function prevents this pattern from being mistaken for a healthy result.
Acquired deficiency may require a search for monoclonal gammopathy, lymphoma, or autoimmune disease. A C1q measurement, serum protein electrophoresis, immunofixation, immunoglobulins, blood count, and other targeted studies may be appropriate.
Discordant and Borderline Results
Discordance is common enough that it should trigger review rather than guesswork. Examples include low function with normal C4, normal function with very low antigen, or results that change dramatically between laboratories.
A structured review considers:
- Was the sample processed correctly? Delayed separation or inadequate freezing can lower function.
- Was replacement therapy given? C1 inhibitor concentrate or plasma can normalize an otherwise abnormal result.
- Were all tests drawn at the same time? Comparing function from one illness with antigen and C4 from another date can create a false pattern.
- Is the laboratory method appropriate? Chromogenic and ELISA methods may differ near the decision threshold.
- Does the clinical picture fit bradykinin angioedema? Recurrent hives and rapid antihistamine response point elsewhere.
- Is the patient an infant? Age-related complement values require caution.
- Could disease be acquired? Late onset and low C1q need a different workup from familial childhood-onset swelling.
Repeat testing should use a new specimen, not simply reanalysis of the same compromised sample. The clinician may contact the laboratory about handling requirements and assay limitations before the next draw.
Genetic testing can help when repeated biochemistry is convincing but not perfectly typical. Finding a pathogenic SERPING1 variant supports HAE type I or II and permits targeted family testing. A negative genetic test does not always overturn strong biochemical evidence because some variants can be difficult to detect or classify.
For suspected HAE with normal C1 inhibitor, a low functional result should first be resolved. That diagnosis requires normal C1 inhibitor quantity and function; it should not become a catch-all label for inconsistent laboratory data.
Diagnosis, Follow-Up, and Safety
A complete diagnostic plan usually includes repeated C1 inhibitor function, C1 inhibitor antigen, and C4. C1q is added when acquired disease is possible. Genetic testing is used when it will clarify classification, family risk, or an uncertain pattern.
Once HAE type I or II is confirmed, care extends beyond the laboratory report. Patients should have access to effective on-demand treatment and know how to use it early. They may also need short-term prevention before high-risk procedures and long-term preventive therapy if attacks are frequent, severe, or disruptive.
Family screening can prevent the first attack from becoming a diagnostic emergency. Relatives who test positive should receive education even if asymptomatic. A written plan, medical identification, and communication with schools, workplaces, dentists, and surgeons can reduce delays in treatment.
The function result should not be used to predict attack severity. A patient with very low activity may have few attacks, while another with a similar value may have frequent disease. Treatment decisions are based on clinical burden, attack sites, patient preference, access, and risk—not on a single percentage.
Routine serial testing is usually unnecessary once a stable hereditary diagnosis is established, unless the specialist is evaluating treatment effect, a conflicting result, or a change in the clinical picture. Repeating function simply to track day-to-day symptoms rarely predicts the next attack.
Airway symptoms require immediate action. Call emergency services for voice change, trouble swallowing, throat tightness, noisy breathing, rapidly increasing tongue swelling, or difficulty breathing. Use prescribed on-demand HAE treatment according to the emergency plan, but do not wait at home to see whether laryngeal swelling improves.
Severe abdominal pain also deserves careful assessment when it is new, unusually intense, associated with fever or bleeding, or unlike prior attacks. HAE can mimic an acute abdomen, but appendicitis, obstruction, infection, ovarian or pregnancy complications, and other emergencies must not be assumed away.
A reliable functional result is powerful because it detects both missing and ineffective C1 inhibitor. Its value comes from disciplined interpretation: correct specimen handling, paired quantity and complement tests, confirmation on a second sample, and a clinical history that matches bradykinin-mediated disease.
Several everyday details can improve the quality of a specialist visit. Patients can record the date, location, duration, suspected trigger, associated abdominal or airway symptoms, and treatment response for each attack. Photographs of visible swelling and copies of emergency-department records can help distinguish deep angioedema from other causes of edema. A medication list should include ACE inhibitors, neprilysin inhibitors, estrogen-containing products, and any complement or C1 inhibitor therapy. These records are often more informative than trying to remember a variable pattern months later.
Testing also has implications before procedures. Dental extraction, endoscopy, intubation, and surgery can trigger swelling in susceptible patients. A confirmed diagnosis allows the treating team to plan short-term prophylaxis, ensure that on-demand medication is available, and prepare for airway management. A borderline laboratory result should not be used casually to authorize or deny prophylaxis; the decision belongs to a clinician who can weigh the procedure, prior attack history, and remaining diagnostic uncertainty.
Pregnancy and hormonal exposure deserve individualized review. Estrogen can worsen attacks in some people, while pregnancy can increase, decrease, or leave attack frequency unchanged. Functional testing itself is safe during pregnancy because it requires only a blood draw, but treatment choices differ. Establishing the diagnosis before pregnancy is helpful, yet an urgent evaluation should proceed at any stage when symptoms suggest HAE.
Finally, a normal functional result should be preserved in context. The date, laboratory, assay method, whether the patient was receiving replacement therapy, and the concurrent antigen and C4 results all matter. A future clinician cannot interpret “normal C1 inhibitor” accurately if it is unclear whether that phrase refers to quantity, function, or both.
References
- The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update 2022 (Guideline)
- The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema and acquired angioedema 2026 (Guideline)
- Evaluating functional C1INH with multiple laboratory methods in patients with suspected hereditary angioedema 2025 (Research Study)
- Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment 2025 (Consensus)
- Angioedema 2024 (Review)
- Cut-off value of C1-inhibitor function for the diagnosis of hereditary angioedema due to C1-inhibitor deficiency 2021 (Research Study)
Disclaimer
C1 inhibitor function is a specialized test that must be interpreted with antigen level, C4, C1q when appropriate, symptoms, treatment timing, and specimen handling. This information does not establish a diagnosis or replace care from an allergy, immunology, or angioedema specialist. Seek emergency help immediately for tongue, throat, voice, swallowing, or breathing symptoms.
